1 The pharmacokinetics of oral loprazolam and pharmacodynamic responses on the morning following nightly drug administration were examined after single and after seven consecutive 1 mg doses in six non-fasting healthy subjects. 2 The serum concentration-time profiles for unchanged loprazolam measured by a specific high pressure liquid chromatography/gas chromatography (h.p.l.c./g.c.) method and for benzodiazepine material measured by radioimmunoassay (RIA) were qualitatively similar although RIA levels were consistently higher. 3 Approximate elimination half-life of unchanged loprazolam after single doses was 8.0 h. For RIA measured material, approximate half-life was 11.7 h following acute administration and 12.8 h after seven consecutive doses. 4 Compared to results after single doses, maximum serum concentration and AUC were greater following 1 week's treatment. Using RIA results, the increases were 27.2% (95% CL 6.9 to 47.4%) and 35.1% (95% CL 15.8 to 54.3%) respectively and using h.p.l.c./g.c. data, 11% (95% CL -22.6% to 44.5%) and 41% (95% CL -50.9 to 133.0%).
Introduction
Loprazolam (Dormonoct, Roussel Laboratories) is a new water soluble 1,4 benzodiazepine with hypnotic properties in man (Boyd & Ankier, 1983; Hindmarch & Clyde, 1980; Salkind & Silverstone, 1983) . Therapy with a hypnotic calls for an approach which differs fundamentally from that where a constant drug effect is required. An intermittent action restricted to the night and avoiding residual effects during the day is desirable. Since these properties are at least to some extent related to circulating active drug, appreciable levels of drug or metabolite should be present during the period of intended sleep but little should persist on awakening, necessitating an agent which displays rapid absorption and elimination. Furthermore, a hypnotic should show minimal accumulation on repeated night time use. This study was carried out to examine the pharmacokinetics of oral loprazolam at the usual clinical dose (1 mg) in healthy subjects after single doses and following repeated administrations for 1 week. In addition, we investigated the degree of accumulation of loprazolam and attempted to determine whether this was of pharmacodynamic significance. To provide information analogous to clinical circumstances, on each occasion the drug was administered at night after an evening meal.
Methods

Subjects
Six healthy males, age 22-37 years, weight 60.3-91.4 kg, none of whom smoked tobacco, participated in the study. The subjects gave written consent for the procedure after full explanation of its purposes and risks. The protocol was approved by the hospital ethics committee.
Study design
The study was carried out in two phases consisting of (a) single doses and (b) repeated doses of loprazolam administered nightly for 7 consecutive nights. The subjects were allocated randomly to the phases, each subject taking each treatment regimen in a balanced, crossover fashion. The treatments were separated by a 2 week drug free interval.
Drugs
Loprazolam was administered as 1 mg tablets. Other drugs, including alcohol, were not permitted from 24 h before each treatment until after completion of each study phase.
Procedure
Loprazolam 1 mg was taken with water (150 ml) at 21.30 h, 2 h after an evening meal and thereafter the subjects refrained from driving or operating machinery until the next morning. The subjects were admitted to hospital overnight on the day of administration of the single dose and on day 7 of repeated dose administration. On these occasions the evening meal was consumed at a constant time (19.30 h); subjects were allowed free choice of meal in the first phase and this was reproduced exactly in the second. The volunteers remained supine until 10 h after treatment, at which time a light breakfast was consumed. Thereafter normal activities were resumed.
On study days, venous blood samples were taken immediately before treatment (0) and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0 (Miller, 1966 Time (h) Figure 1 Mean serum loprazolam concentration-time profiles after single (-*-) and seven repeated (-a-) doses in six healthy subjects using results from h.p.l.c./g.c. and RIA analyses. Loprazolam 1 mg administered at time zero. Standard deviations omitted for clarity (see Table 1 ). .1 64 C0 < C ng ml-[) after loprazolam 1 mg. Futhermore, the h.p.l.c./g.c. assay has relatively high variability (coefficient of variation 17-20%) at the range of concentrations in this study (Stevens et al., 1983) . These factors undoubtedly contributed to the difficulties experienced in defining pharmacokinetic parameters.
Serum drug levels measured by RIA were consistently higher than those of unchanged loprazolam as assessed by chromatography and the differences were particularly marked at late time points where the RIA method may be subject to interference. Since this assay is specific for loprazolam-like benzodiazepines, it must be concluded that the distortion of the serum profiles compared to those of the parent drug represents benzodiazepine structure(s) which are presumably metabolite(s) of loprazolam. The major biotransformation product in man is the piperazine N-oxide (Illing & McLean, unpublished data) which occurs in appreciable concentrations (approximately 50% of those of unchanged loprazolam) and has an elimination half-life of the same order as the parent drug but the time course of its appearance would tend to accentuate levels measured by RIA during the terminal elimination phase of loprazolam. When the RIA method is used to assess loprazolam concentrations, the appearance of this or other metabolites could lead to spurious prolongation of half-life and exaggerate apparent accumulation. However, since the piperazine N-oxide of loprazolam may have pharmacological activity approaching that of the parent drug (Miller, unpublished Our findings provide evidence that the absorption of loprazolam can be slow. Mean time to peak serum concentration was considerably greater than that usually quoted for benzodiazepines used as hypnotics (Breimer, 1979;  0E Curry & Whelpton, 1979; Greenblatt et al., 1981; Kangas & Breimer, 1981) and there was a marked lag time, on average 1-1.5 h after drug administration, before loprazolam was detectable in serum. Although onset of activity depends on concentration-effect relationships which are unknown for loprazolam, rate of absorption is usually the rate limiting factor in the transfer of drug molecules to their sites of action in the central nervous system, after oral dosing (Curry & Whelpton, 1979) . Thus loprazolam is unlikely to have a rapid pharmacological effect. In this study, however, the hypnotic was administered at night after food, which is the usual clinical practice, rather than in the morning after an overnight fast which is the rule in pharmacokinetic studies. Diurnal variability in the absorption of benzodiazepines has been reported (Chamberlain et al., 1981) and this may lead to delayed peak levels when the drug is taken at night. Furthermore, secondary peaks of unchanged loprazolam and RIA measured material occurred frequently. Similar observations have been made with loprazolam (Stevens et al., 1983) and other benzodiazepines (Breimer etal., 1977; Kangas & Breimer, 1981; Korttila & Kangas, 1977) and may relate to ingestion of food. Where secondary peaks represent the maximum serum concentrations of the drug, they may have an important influence on the assessment of absorption, but whether they denote pharmacologically active drug remains to be established. Until comparisons with other benzodiazepine hypnotics after night time dosing and food are available, it is premature to ascribe undue importance to the rate of absorption and pharmacokinetic profiles of loprazolam in the circumstances of this study.
Loprazolam 1 mg satisfies certain pharmacokinetic requirements for a useful hypnotic agent. It is eliminated relatively rapidly and there is trivial accumulation after repeated nightly doses. Our half-life estimates place loprazolam in the category of benzodiazepines expected to have short-intermediate duration of action (Greenblatt et al., 1981) . However, the slow development of peak serum levels and the absence of a marked distribution phase leading to appreciable serum drug concentrations 12 h after ingestion support the conclusion that loprazolam 1 mg may have a persistent effect on performance on the day following night time administration (Nicholson & Stone, 1983) . Amrein etal. (1983) have attempted to determine the potential use of benzodiazepines on the basis of their pharmacokinetic profile using the residual fraction-the quotient of drug concentration at 12 h after oral intake to maximum drug concentration. In the study reported here, residual fraction for unchanged loprazolam after single doses was 0.44 and after repeated doses 0.47. Inspection of the results of another study of the pharmacokinetics of unchanged loprazolam (Stevens et al., 1983) allows the calculation of similar residual quotients. Furthermore, in clinical use, loprazolam taken at night is associated with a mean decrease in daytime anxiety (Morgan & Oswald, 1982) . These observations suggest a potential role for loprazolam as a hypnotic with anxiolytic properties the next day.
There were marked interindividual differences in absorption rate of loprazolam as assessed by time to peak concentration and maximum serum concentration achieved. Biopharmaceutical factors governing the rate and extent of absorption are important in this respect (Breimer, 1979) . It is not yet determined whether the irregularities and variability in loprazolam absorption are due to the physico-chemical characteristics of loprazolam or to its pharmaceutical formulation but such diversity in pharmacokinetic factors may have important consequences in terms of intersubject variability in onset and extent of drug action.
In conclusion, loprazolam is absorbed slowly after ingestion at night following food and although its elimination half-life suggests a short to intermediate duration of action appreciable drug concentrations persist the next day. On repeated doses, there is a minor degree of pharmacokinetic accumulation. It would appear that the principal role of loprazolam may be in the management of disturbed sleep secondary to daytime anxiety.
